MetLife Investment Management’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-84,197
| Closed | -$345K | – | 2945 |
|
|
2022
Q1 | $345K | Buy |
84,197
+47,767
| +131% | +$173K | ﹤0.01% | 2010 |
|
|
2021
Q4 | $130K | Sell |
36,430
-23,939
| -40% | -$83.7K | ﹤0.01% | 2307 |
|
|
2021
Q3 | $220K | Buy |
60,369
+20,612
| +52% | +$83.3K | ﹤0.01% | 2028 |
|
|
2021
Q2 | $173K | Sell |
39,757
-27,056
| -40% | -$110K | ﹤0.01% | 2242 |
|
|
2021
Q1 | $275K | Buy |
66,813
+19,845
| +42% | +$86K | ﹤0.01% | 1871 |
|
|
2020
Q4 | $187K | Buy |
46,968
+9,208
| +24% | +$29.8K | ﹤0.01% | 2018 |
|
|
2020
Q3 | $102K | Sell |
37,760
-31,821
| -46% | -$88.1K | ﹤0.01% | 2204 |
|
|
2020
Q2 | $191K | Hold |
69,581
| – | – | ﹤0.01% | 1935 |
|
|
2020
Q1 | $164K | Hold |
69,581
| – | – | ﹤0.01% | 1798 |
|
|
2019
Q4 | $327K | Hold |
69,581
| – | – | ﹤0.01% | 1693 |
|
|
2019
Q3 | $233K | Hold |
69,581
| – | – | ﹤0.01% | 1864 |
|
|
2019
Q2 | $229K | Hold |
69,581
| – | – | ﹤0.01% | 1951 |
|
|
2019
Q1 | $211K | Hold |
69,581
| – | – | ﹤0.01% | 1954 |
|
|
2018
Q4 | $189K | Hold |
69,581
| – | – | ﹤0.01% | 1937 |
|
|
2018
Q3 | $234K | Sell |
69,581
-2,150
| -3% | -$6.64K | ﹤0.01% | 2004 |
|
|
2018
Q2 | $185K | Hold |
71,731
| – | – | ﹤0.01% | 1954 |
|
|
2018
Q1 | $158K | Buy |
71,731
+52,911
| +281% | +$119K | ﹤0.01% | 2015 |
|
|
2017
Q4 | $37K | Buy |
+18,820
| New | +$41K | ﹤0.01% | 2215 |
|
Other funds holding ATRS
MetLife Investment Management's ATRS Position: Q2 2022 in Review
MetLife Investment Management sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 84,197 shares — an estimated $345K sold.
MetLife Investment Management first reported a position in ATRS in Q4 2017 and held it in 18 quarters. The position peaked at $345K in Q1 2022. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- MetLife Investment Management reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- MetLife Investment Management sold 84,197 Antares Pharma, Inc. shares in Q2 2022, an estimated $345K.
- MetLife Investment Management first reported a position in Antares Pharma, Inc. in Q4 2017 and held it in 18 quarters.
- MetLife Investment Management's Antares Pharma, Inc. position peaked at $345K in Q1 2022.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on MetLife Investment Management's 13F filing for Q2 2022, filed 11 Aug 2022.